

43550

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Saliha MOUSSAOUI-MRABET et al.

Group Art Unit: TBA

Serial No.: 10/088,138

Examiner: TBA

Filed: 15 March 2002

For: NOVEL ANIMAL MODEL OF  
ALZHEIMER DISEASE WITH AMYLOID  
PLAQUES AND MITOCHONDRIAL  
DYSFUNCTIONSINFORMATION DISCLOSURE STATEMENTAssistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. §§ 1.56 and 1.97-1.98, Applicants hereby notify the Examiner of documents that may be deemed material to the examination of the above-identified application. Copies are attached hereto.

As the instant Information Disclosure Statement is being filed prior to issuance of a first Office Action on the merits, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(b) is required.


Also, the documents are in English and therefore, no brief statement of relevance is required.

INFORMATION DISCLOSURE STATEMENT  
U.S. Serial No.: 10/088,138

**CONCLUSION**

Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the instant application.

Respectfully submitted,



Daryl A. Basham  
Reg. No. 45,869

Roylance, Abrams, Berdo  
& Goodman, L.L.P.  
1300 19<sup>th</sup> Street, N.W., Suite 600  
Washington, D.C. 20036-2680  
(202) 659-9076

Dated: 23 September 2002

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1 of

1

*Complete if Known*

Application Number	10/088,138
Filing Date	15 March 2002
First Named Inventor	MOUSSAOUI-MRABET
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	43550

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code (if known)			
		US-5898094	04-27-1999	Duff et al.	
		US-5888498	03-30-1999	Davis et al.	
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code-Number- Kind Code (if known)				
		WO-9817782	04-30-1998	Univ. of South Florida		
		WO-9634097	10-31-1996	Cephalon, Inc.		
		WO-9526973	10-12-1995	Applied Genetics, Inc.		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publishers, city and/or country where published	T
		TALPADE et al., "Profound mitochondrial dysfunction in transgenic mice over-expressing V717F beta-amyloid precursor protein." Soc. Neurosci: Abstr. (1998) 24(1-2):729.	
		BEGLEY et al., "Altered calcium hemostasis and mitochondrial dysfunction in critical synaptic compartments of presenilin-1 Mutant Mice.", J. Neurochem. (1999) 72(3):1030-1039.	
		GOU et al., "Calbindin D28k blocks the proapoptotic actions of mutant presenilin 1: reduced oxidative stress and preserved mitochondrial function." Proc. Natl. Acad. Sci. USA (1998) 95(6):3227-3232.	
		SMITH et al., "Amyloid-β deposition in alzheimer transgenic mice is associated with oxidative stress." J. Neurochem., (1998) 70(5):2212-2215.	
		PARADIS et al., "Amyloid β peptide of alzheimer's disease downregulates bcl-2 and upregulates bax expression in human neurons.", J. Neurosci. (1996) 16(23):7533-7539.	
Examiner Signature		Date Considered	